科伦博泰生物(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06990 科伦博泰生物

休市中 05-29 16:08:26

462.000

+15.000

+3.36%

最高472.600	最低438.400	成交量219.07万
今开458.200	昨收447.000	日振幅7.65%
总市值1,076亿	流通市值789.95亿	总股本2.33亿
成交额10.10亿	换手率1.28%	流通股本1.71亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"科伦博泰生物","latestPrice":462,"timestamp":1780042106008,"preClose":447,"halted":0,"volume":2190677,"delay":0,"changeRate":0.03355704697986577,"floatShares":170984257,"shares":233000000,"eps":-1.9197694235064542,"marketStatus":"休市中","change":15,"latestTime":"05-29 16:08:26","open":458.2,"high":472.6,"low":438.4,"amount":1009662484,"amplitude":0.07651,"askPrice":462,"askSize":136600,"bidPrice":460.4,"bidSize":14900,"shortable":3,"etf":0,"ttmEps":-1.9197694235064542,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780277400000},"marketStatusCode":7,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":447,"openAndCloseTimeList":[[1780018200000,1780027200000],[1780030800000,1780041600000]],"volumeRatio":2.288056215205344,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06990","defaultTab":"news","newsList":[{"id":"1164683867","title":"异动解读 | 科伦博泰生物盘中大跌5.02%，科伦系业绩失速引发获利回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1164683867","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164683867?lang=zh_cn&edition=full","pubTime":"2026-05-28 14:10","pubTimestamp":1779948634,"startTime":"0","endTime":"0","summary":"科伦博泰生物(06990)今日盘中出现大跌，跌幅达5.02%。消息面上，此次下跌主要源于市场对科伦系公司基本面的重新审视。此前，科伦博泰因ASCO年会临床数据利好及机构上调目标价等因素连续上涨，积累了较多获利盘。然而，近期披露的财务数据显示，科伦博泰2025年虽营收增长6.5%，但净亏损扩大至3.82亿元，主要因授权及里程碑收入大幅减少、研发与商业化投入高企所致。同时，其母公司科伦药业及关联公司川宁生物的核心盈利指标也出现全线大幅下滑。这种“增收不增利”的财务现实，与市场此前对其研发管线的乐观预期形成落差，导致部分资金选择获利了结，从而对股价形成压力。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176584183","title":"异动解读｜科伦博泰生物盘中下跌3.21%，科伦系业绩全面失速引发获利回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1176584183","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176584183?lang=zh_cn&edition=full","pubTime":"2026-05-28 13:03","pubTimestamp":1779944620,"startTime":"0","endTime":"0","summary":"5月28日，科伦博泰生物盘中下跌3.21%，报458.8港元，成交额1.15亿港元。消息面上，此前科伦博泰连续多日因ASCO年会临床数据利好及野村上调目标价等催化大幅上涨，但近日有关科伦系\"三驾马车\"全面失速的报道引发市场对基本面的重新审视。据披露，科伦博泰2025年营收20.58亿元，同比增长6.5%，但净亏损扩大至3.82亿元，较上年同期亏损2.67亿元进一步恶化，主要原因为授权及里程碑收入同比大幅减少、研发费用与商业化投入高企。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101504322","title":"异动解读｜科伦博泰生物盘中上涨3.07%，野村上调目标价叠加ASCO年会重磅数据持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1101504322","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101504322?lang=zh_cn&edition=full","pubTime":"2026-05-27 13:45","pubTimestamp":1779860739,"startTime":"0","endTime":"0","summary":"5月27日，科伦博泰生物盘中上涨3.07%，报477.0港元，成交额1.26亿港元。消息面上，野村近日上调公司目标价至544.42港元并维持\"买入\"评级，认为其TROP2 ADC药物sac-TMT联合帕博利珠单抗一线治疗PD-L1阳性非小细胞肺癌的III期临床数据令人鼓舞，PFS风险比达0.35，OS亦呈积极趋势（HR=0.55），系全球首个在该适应症III期中显示PFS改善的ADC药物。此外，公司多项注册研究入选ASCO年会口头报告专场，管线全球价值兑现预期持续催化股价表现。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638159201","title":"大行评级丨野村：上调科伦博泰生物目标价至544.42港元，维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2638159201","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638159201?lang=zh_cn&edition=full","pubTime":"2026-05-26 16:47","pubTimestamp":1779785222,"startTime":"0","endTime":"0","summary":"野村发表报告指，科伦博泰生物将于即将举行的2026年美国临床肿瘤学会年会上，公布其TROP-2 ADC药物sac-TMT的OptiTROP-Lung05临床试验结果。该行认为，这组数据相当鼓舞人心，是首个在针对PD-L1阳性NSCLC患者的III期试验中显示PFS改善的ADC药物。　　该行维持科伦博泰“买入”评级，基于现金流折现模型，目标价由438.3港元上调至544.42港元，此举同时反映了因销售前景更佳而将终端增长率假设由4%上调至4.5%，加权平均资本成本则维持10.8%不变。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260526/32254804.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["EWH","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638064567","title":"董事长大秀肌肉难阻公司业绩收缩，科伦系“三驾马车”全面失速","url":"https://stock-news.laohu8.com/highlight/detail?id=2638064567","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638064567?lang=zh_cn&edition=full","pubTime":"2026-05-26 12:04","pubTimestamp":1779768249,"startTime":"0","endTime":"0","summary":"“三驾马车”全面失速根据科伦药业2025年年度报告，公司全年实现营业总收入185.13亿元，同比下降15.13%；归属于上市公司股东的净利润17.02亿元，同比大幅下滑42.03%；扣除非经常性损益后净利润15.97亿元，同比下降44.99%，为近五年来首次营收、净利双降。科伦系另一家A股上市公司业绩同样不乐观。2026年起科伦系有望迎来边际修复。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1779766804153183417","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["06990","BK0060","BK1161","301301","LU1064130708.USD","LU0196878994.USD","LU1979443071.USD","LU2148510915.USD","002422","MSD","LU1934453819.USD","BK0239","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108779178","title":"异动解读｜科伦博泰生物盘中上涨3.12%，ASCO年会重磅数据持续催化管线价值重估","url":"https://stock-news.laohu8.com/highlight/detail?id=1108779178","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108779178?lang=zh_cn&edition=full","pubTime":"2026-05-26 10:19","pubTimestamp":1779761970,"startTime":"0","endTime":"0","summary":"5月26日，科伦博泰生物盘中上涨3.12%，报483.8港元，成交额1.87亿港元。消息面上，公司近期研发利好密集释放，持续催化股价表现。公司此前公告将在ASCO年会上公布多项临床研究成果，核心产品TROP2 ADC芦康沙妥珠单抗及RET抑制剂富马酸仑博替尼两项注册研究入选转移性非小细胞肺癌口头报告专场。此外，中邮证券首次覆盖公司并给予\"买入\"评级，认为管线全球价值兑现在即。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638534935","title":"格隆汇个股放量排行榜 | 5月25日","url":"https://stock-news.laohu8.com/highlight/detail?id=2638534935","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638534935?lang=zh_cn&edition=full","pubTime":"2026-05-25 17:30","pubTimestamp":1779701404,"startTime":"0","endTime":"0","summary":"股票名称成交额（万）量比持续放量天数天利控股集团26177.222.493百富环球2703.382.425中联发展控股1067.482.361优必选217973.061.981华润医疗1719.231.911滔搏3529.591.832胜宏科技350159.461.791数码通电讯961.431.781九龙仓集团17387.851.641蔚来-SW46990.051.551高鑫零售1589.461.521科伦博泰生物60133.001.496九福来102.461.451中集集团7903.471.441北大青鸟环宇360.511.371PACIFIC LEGEND740.851.361中海油田服务9347.601.361MOS HOUSE695.301.331百果园集团641.011.291中芯国际1651388.781.282量化派3423.981.231佰泽医疗5107.781.191时代天使8886.501.192五一视界215348.591.182稀美资源-五百6200.381.1710电讯盈科6323.451.171美格智能7545.751.171深圳高速公路股份1185.201.172森松国际19247.321.143兖矿能源47039.851.111大象未来集团855.821.091通通AI社交2016.021.061兆易创新243","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/25173057187788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02714","06990","08547","02155","06613","01516","03888","03986","02609","02259","02685","01592","00152","00081","00981","02418","00177","06699","01919","00004","00165","01477","00117","06110","00909","02587","00199","02291","02142","09926","09869","01672","01473","09866","00008","06603","02050","02172","02506","02565","00384","00107","06681","09626","06955","00087","09880","09993","02598","01211"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2637397173","title":"中邮证券：首次覆盖科伦博泰生物(06990)给予“买入”评级 管线全球价值兑现在即","url":"https://stock-news.laohu8.com/highlight/detail?id=2637397173","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637397173?lang=zh_cn&edition=full","pubTime":"2026-05-22 16:57","pubTimestamp":1779440240,"startTime":"0","endTime":"0","summary":"公司是开发抗体偶联药物(ADC)的先行者之一，已积累十余年ADC研发经验，亦是首家与前十大生物制药跨国公司建立ADC合作的中国公司。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260522/20260522165747_67177.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260522/20260522165747_67177.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445059.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["161027","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191401929","title":"异动解读｜科伦博泰生物盘中上涨7.58%，ASCO年会肺癌III期临床达主要终点叠加多项口头报告入选","url":"https://stock-news.laohu8.com/highlight/detail?id=1191401929","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191401929?lang=zh_cn&edition=full","pubTime":"2026-05-22 09:36","pubTimestamp":1779413789,"startTime":"0","endTime":"0","summary":"5月22日，科伦博泰生物盘中上涨7.58%，报479.8港元，成交额1.47亿港元。消息面上，公司当日公告将在ASCO年会上公布多项临床研究成果，核心产品TROP2 ADC芦康沙妥珠单抗及RET抑制剂富马酸仑博替尼两项注册研究入选转移性非小细胞肺癌口头报告专场。数据显示，sac-TMT联合帕博利珠单抗一线治疗PD-L1阳性晚期非小细胞肺癌的III期临床已达主要终点，较单药显著延长无进展生存期，客观缓解率提升至70.2%，安全性总体可控。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125854209","title":"异动解读 | ASCO年会公布积极临床数据，科伦博泰生物盘中大涨5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=1125854209","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125854209?lang=zh_cn&edition=full","pubTime":"2026-05-22 09:31","pubTimestamp":1779413472,"startTime":"0","endTime":"0","summary":"科伦博泰生物今日盘中大涨5.16%，引起了市场的广泛关注。消息面上，公司宣布将于2026年美国临床肿瘤学会年会上公布多项临床研究成果，其中核心产品TROP2 ADC芦康沙妥珠单抗及RET抑制剂富马酸仑博替尼两项注册研究入选转移性非小细胞肺癌口头报告专场。数据显示，sac-TMT联合帕博利珠单抗一线治疗PD-L1阳性晚期非小细胞肺癌的III期临床试验达到主要终点，与单药相比显著延长无进展生存期，客观缓解率提升至70.2%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126174012","title":"异动解读｜科伦博泰生物开盘上涨5.34%，ASCO年会多项注册研究入选口头报告叠加III期临床接连告捷","url":"https://stock-news.laohu8.com/highlight/detail?id=1126174012","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126174012?lang=zh_cn&edition=full","pubTime":"2026-05-22 09:23","pubTimestamp":1779413022,"startTime":"0","endTime":"0","summary":"5月22日，科伦博泰生物开盘上涨5.34%，报477.8港元，成交额586.45万港元。消息面上，公司当日公告将在2026年ASCO年会上公布多项临床研究成果，其中核心产品TROP2 ADC芦康沙妥珠单抗及RET抑制剂富马酸仑博替尼两项注册研究入选转移性非小细胞肺癌口头报告专场。此外，公司与默沙东合作的sac-TMT在子宫内膜癌III期TroFuse-005研究中已成功达到OS与PFS双主要终点，多项全球III期临床接连告捷持续催化股价表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637728368","title":"科伦博泰生物(06990)：于2026年美国临床肿瘤学会年会上公布的多项创新药物研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2637728368","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637728368?lang=zh_cn&edition=full","pubTime":"2026-05-22 07:36","pubTimestamp":1779406592,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物 发布公告，本公司将在于2026年5月29日至6月2日于美国伊利诺伊州芝加哥市举行的2026年美国临床肿瘤学会年会上公布多项公司主导的临床研究成果，其中靶向人滋养细胞表面抗原2抗体偶联药物芦康沙妥珠单抗(佳泰莱)、新一代选择性转染过程中重排抑制剂富马酸仑博替尼两项注册研究入选转移性非小细胞肺癌口头报告专场。上述研究的完整摘要已于当地时间2026年5月21日发布在ASCO的官方网站上。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444809.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0196878994.USD","159992","06990","BK1574","BK1161","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180586961","title":"科伦博泰生物：肺癌三期试验显示，Sacituzumab Tirumotecan联合帕博利珠单抗显著延长无进展生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1180586961","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180586961?lang=zh_cn&edition=full","pubTime":"2026-05-22 05:04","pubTimestamp":1779397496,"startTime":"0","endTime":"0","summary":"在针对肺癌的第三期临床试验中，科伦博泰生物（SKB BIO）的研究数据显示，其药物Sacituzumab Tirumotecan与帕博利珠单抗（Pembrolizumab）联合治疗方案，相较于单独使用帕博利珠单抗，显著延长了患者的无进展生存期（PFS）。这一积极结果凸显了联合疗法在提升疗效方面的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2491049909.HKD","BK4534","LU0196878994.USD","LU1983299246.USD","LU0320765646.SGD","IE00BLSP4452.SGD","LU0130517989.USD","LU0980610538.SGD","002422","SG9999002224.SGD","LU0203345920.USD","LU1116320737.USD","SG9999014559.SGD","LU0106261372.USD","LU0070302665.USD","LU1035773651.USD","LU1585245621.USD","LU1923622614.USD","LU2357627491.SGD","LU2361044949.HKD","LU0211331839.USD","LU0861579265.USD","LU0868494617.USD","BK4516","LU1066051811.HKD","BK4585","LU2125909593.SGD","IE00BBT3K403.USD","SG9999001176.USD","LU2106854487.HKD","LU1066053197.SGD","LU1699723380.USD","SG9999014567.USD","LU0098860793.USD","BK4550","LU0208291251.USD","LU0648001328.SGD","IE00BFTCPJ56.SGD","LU0859254822.USD","LU1023059063.AUD","LU2324357040.USD","LU0477156953.USD","LU2125154935.USD","LU1929549753.HKD","SGXZ57979304.SGD","LU1066051498.USD","LU1057294990.SGD","SG9999014575.USD","BK4559","LU1571399168.USD","LU2023250843.SGD","LU1934455277.USD","LU1989772923.USD","LU0238689110.USD","LU1291159041.SGD","LU0265550946.USD","LU1941712264.USD","IE0002141913.USD","SG9999002232.USD","LU0266013472.USD","IE00BJJMRZ35.SGD","LU1430594728.SGD","SG9999013999.USD","SG9999015341.SGD","LU0942090050.USD","LU0868494708.USD","IE000M9KFDE8.USD","LU2433249047.HKD","LU2468319806.SGD","SG9999015358.SGD","SG9999001176.SGD","BK4007","LU1066051225.USD","LU2023250504.SGD","LU0058720904.USD","LU1093756325.SGD","LU1061106388.HKD","LU1162221912.USD","LU2461242641.AUD","LU2491050071.SGD","LU1974910355.USD","LU0965509283.SGD","LU1037948897.HKD","IE00BJT1NW94.SGD","LU1093756168.USD","LU2089984988.USD","IE00B1BXHZ80.USD","BK4533","LU2125154778.USD","LU2361045086.USD","LU0432979614.USD","LU0130102774.USD","LU1934455863.HKD","LU2360032135.SGD","IE00BSNM7G36.USD","LU2361044865.SGD","LU2491050154.USD","IE00B2B36J28.USD","LU1989771016.USD","06990","LU0122379950.USD","IE0009355771.USD","LU0965509101.SGD","LU1941712348.USD","IE00BN8TJ469.HKD","LU2125909247.SGD","BK1161","LU1037948541.HKD","SG9999001440.SGD","SG9999014542.SGD","LU0203347892.USD","LU0985320562.USD","BK4588","LU0289739699.SGD","LU1116320901.HKD","LU2112291526.USD","IE00BLSP4239.USD","LU1917777945.USD","LU1989772840.SGD","LU1934455194.USD","LU0965509010.AUD","LU1201861249.SGD","LU0320765489.SGD","LU1069347547.HKD","LU0006306889.USD","IE00B4R5TH58.HKD","LU0965508806.USD","LU0234572021.USD","LU0265550359.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105243252","title":"科伦博泰生物与默沙东联合疗法安全性概览：Sac-TMT联合帕博利珠单抗总体可控，与各组分已知安全性特征一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1105243252","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105243252?lang=zh_cn&edition=full","pubTime":"2026-05-22 05:04","pubTimestamp":1779397489,"startTime":"0","endTime":"0","summary":"科伦博泰生物与默沙东联合开发的Sac-TMT与帕博利珠单抗（Pembrolizumab）联合治疗方案，其安全性特征总体而言是可控的。观察到的安全性数据与各单药组分已知的安全性特征保持一致，未出现超出预期的新的安全性信号。这一结果表明，该联合疗法的安全性在临床上处于可管理范畴，为其进一步的临床开发与应用提供了支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014559.SGD","BK4559","LU2361044865.SGD","LU1585245621.USD","LU0985320562.USD","SG9999002224.SGD","SG9999014542.SGD","LU1989772923.USD","IE00BJT1NW94.SGD","LU0965509101.SGD","SG9999014567.USD","LU1983299246.USD","LU2360032135.SGD","LU1035773651.USD","LU0289739699.SGD","LU2106854487.HKD","LU0477156953.USD","IE00BLSP4452.SGD","LU0106261372.USD","LU1929549753.HKD","LU2023250843.SGD","LU0130517989.USD","BK4533","LU1699723380.USD","LU2125154935.USD","LU0942090050.USD","LU1941712264.USD","SG9999014575.USD","LU0266013472.USD","LU1571399168.USD","LU1116320737.USD","LU0208291251.USD","LU0965509283.SGD","LU0130102774.USD","BK4007","LU1934455194.USD","IE0002141913.USD","LU0965509010.AUD","LU1037948541.HKD","LU0868494617.USD","SG9999013999.USD","IE00B1BXHZ80.USD","LU2023250504.SGD","LU0265550946.USD","SG9999015358.SGD","LU1934455863.HKD","LU0058720904.USD","LU1116320901.HKD","06990","LU0196878994.USD","LU1917777945.USD","LU1941712348.USD","LU2468319806.SGD","LU2491049909.HKD","LU1057294990.SGD","LU2125154778.USD","LU2433249047.HKD","LU0320765489.SGD","LU0203345920.USD","IE00BN8TJ469.HKD","LU0006306889.USD","IE00BBT3K403.USD","SG9999002232.USD","LU2357627491.SGD","LU0238689110.USD","LU1291159041.SGD","BK4588","SG9999015341.SGD","LU2089984988.USD","LU2125909247.SGD","LU0868494708.USD","SG9999001176.USD","LU1069347547.HKD","BK4534","LU0211331839.USD","LU1066053197.SGD","LU2361044949.HKD","LU1989772840.SGD","LU0070302665.USD","BK1161","LU1923622614.USD","LU2491050071.SGD","LU0122379950.USD","LU2125909593.SGD","LU2324357040.USD","LU1430594728.SGD","LU1201861249.SGD","LU0432979614.USD","LU1974910355.USD","MRK","IE00B4R5TH58.HKD","LU1093756325.SGD","SG9999001440.SGD","IE0009355771.USD","LU2491050154.USD","LU1023059063.AUD","SG9999001176.SGD","BK4585","LU1066051498.USD","LU0965508806.USD","LU0265550359.USD","LU1162221912.USD","BK4516","LU0320765646.SGD","LU0980610538.SGD","LU1061106388.HKD","LU0203347892.USD","IE00BFTCPJ56.SGD","LU1934455277.USD","IE00B2B36J28.USD","LU0861579265.USD","IE00BLSP4239.USD","LU2112291526.USD","LU2361045086.USD","IE000M9KFDE8.USD","IE00BJJMRZ35.SGD","LU0648001328.SGD","IE00BSNM7G36.USD","SGXZ57979304.SGD","LU1066051811.HKD","LU0098860793.USD","BK4550","LU0859254822.USD","LU1093756168.USD","LU2461242641.AUD","LU1989771016.USD","LU1037948897.HKD","LU0234572021.USD","LU1066051225.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637780378","title":"港股异动 | 科伦博泰生物(06990)涨超5% 与默沙东合作的TROP2 ADC全球III期研究达成主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2637780378","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637780378?lang=zh_cn&edition=full","pubTime":"2026-05-21 10:58","pubTimestamp":1779332292,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物涨超5%，截至发稿，涨3.3%，报451.4港元，成交额1.66亿港元。消息面上，近日，据科伦博泰生物官微消息，默沙东宣布，与公司合作开发的在研TROP2靶向抗体药物偶联物sacituzumab tirumotecan，在针对某些晚期或复发性子宫内膜癌患者的关键性III期TroFuse-005试验中，达到了总生存期和无进展生存期的主要终点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444337.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2360032135.SGD","BK1161","LU1037948541.HKD","LU1989772840.SGD","LU1116320737.USD","LU0965508806.USD","LU1941712264.USD","SG9999001440.SGD","IE00BJJMRZ35.SGD","LU2125909247.SGD","LU0070302665.USD","BK4585","LU0432979614.USD","LU0861579265.USD","LU1066051498.USD","LU1974910355.USD","BK4007","LU0106261372.USD","LU0006306889.USD","LU0203345920.USD","LU0859254822.USD","LU2361045086.USD","BK4550","LU1941712348.USD","SGXZ57979304.SGD","LU1934455863.HKD","SG9999014575.USD","LU0477156953.USD","LU0203347892.USD","LU0234572021.USD","LU1057294990.SGD","LU1066053197.SGD","SG9999015341.SGD","IE00B4R5TH58.HKD","LU0266013472.USD","LU1983299246.USD","IE0002141913.USD","LU0980610538.SGD","LU2491049909.HKD","SG9999002232.USD","SG9999002224.SGD","LU1069347547.HKD","LU1430594728.SGD","IE00BLSP4239.USD","LU0130102774.USD","LU1917777945.USD","SG9999014559.SGD","BK4134","LU2361044865.SGD","LU1923622614.USD","BK4588","LU0965509283.SGD","LU2324357040.USD","IE00BLSP4452.SGD","LU1061106388.HKD","LU2106854487.HKD","BK4533","IE00BFTCPJ56.SGD","LU2361044949.HKD","LU2125154778.USD","LU1571399168.USD","LU0868494617.USD","LU1201861249.SGD","SG9999014542.SGD","IE00B1BXHZ80.USD","LU2125909593.SGD","IE00BJT1NW94.SGD","LU2089984988.USD","LU1093756325.SGD","LU2491050071.SGD","LU0208291251.USD","LU1023059063.AUD","LU1066051225.USD","LU0265550359.USD","LU0238689110.USD","BK4080","LU0985320562.USD","06990","SG9999001176.USD","LU1162221912.USD","LU1929549753.HKD","LU0196878994.USD","IE00B2B36J28.USD","IE00BN8TJ469.HKD","LU0648001328.SGD","LU2468319806.SGD","LU1934455277.USD","SG9999014567.USD","BK4516","IE000M9KFDE8.USD","LU0098860793.USD","LU1037948897.HKD","LU0868494708.USD","BK4559","LU0320765489.SGD","BK4534","LU0130517989.USD","LU2112291526.USD","IE0009355771.USD","LU1066051811.HKD","IE00BBT3K403.USD","MRK","LU0942090050.USD","SG9999001176.SGD","LU0211331839.USD","LU2433249047.HKD","LU0265550946.USD","LU0320765646.SGD","LU1291159041.SGD","LU1093756168.USD","LU2461242641.AUD","LU2491050154.USD","LU1585245621.USD","IE00BSNM7G36.USD","LU2357627491.SGD","LU0965509101.SGD","LU2023250843.SGD","LU1989772923.USD","SG9999013999.USD","LU1989771016.USD","LU0965509010.AUD","LU0289739699.SGD","BK4231","LU1934455194.USD","LU2125154935.USD","LU1699723380.USD","LU1116320901.HKD","LU0058720904.USD","LU2023250504.SGD","SG9999015358.SGD","LU1035773651.USD","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188851059","title":"异动解读｜科伦博泰生物盘中上涨3.52%，TROP2 ADC三期临床成功叠加管线利好持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1188851059","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188851059?lang=zh_cn&edition=full","pubTime":"2026-05-21 09:52","pubTimestamp":1779328332,"startTime":"0","endTime":"0","summary":"5月21日，科伦博泰生物盘中上涨3.52%，报454.6港元，成交额5097.34万港元。消息面上，默沙东近日公告其从科伦博泰引进的TROP2抗体偶联药物芦康沙妥珠单抗在全球III期TroFuse-005临床中成功达到总生存期与无进展生存期两项主要终点，适应症为晚期或复发性子宫内膜癌，系全球首个在该适应症证明OS和PFS双重改善的III期ADC临床。此外，公司PD-1×VEGF双特异性抗体SKB118的IND已获国家药监局批准，适应症为晚期实体瘤，多重研发里程碑持续催化股价表现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636885146","title":"生物医药板块盘初普涨 药明合联(02268)涨5.24%、百济神州(06160)涨2.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636885146","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636885146?lang=zh_cn&edition=full","pubTime":"2026-05-19 09:46","pubTimestamp":1779155169,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股生物医药板块盘初普涨，截至发稿，药明合联 涨5.24%，科伦博泰生物涨4.01%，百济神州涨2.17%，诺诚健华涨2.00%，药明生物涨1.58%，康诺亚-B涨1.35%，金斯瑞生物科技涨1.12%。消息面上，中邮证券研究表示，26年有望迎来BD和重点项目数据读出的双重催化，国产创新药全球性竞争力提升逻辑不断强化。建议关注确定性高、BD预期扰动相对小的标的。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981657","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1688375341.USD","06160","LU0708995583.HKD","161726","LU0516422440.USD","09969","BK1589","LU0456846285.SGD","LU1719994722.HKD","LU0417516738.SGD","LU0417516902.SGD","LU0348825331.USD","LU0823426308.USD","LU0052750758.USD","LU1770034418.SGD","688235","02269","XBI","06990","LU0039217434.USD","LU0516422366.SGD","LU1242518931.SGD","SG9999002562.SGD","LU1303224171.USD","LU0307460666.USD","02268","LU1251922891.USD","LU3063872942.SGD","BK4588","IE00B0JY6N72.USD","BK1161","01548","LU0181495838.USD","ONC","399441","HK0000306701.USD","LU0359201612.USD","BK4581","BK1576","BK1141","BK1574","BK1583","BK1588","HK0000320264.USD","LU0588546209.SGD","SG9999014674.SGD","LU0043850808.USD","LU0359202008.SGD","LU0320764599.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636788370","title":"港股异动 | 科伦博泰生物(06990)早盘涨超5% 默沙东TROP2靶向ADC疗法3期临床成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2636788370","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636788370?lang=zh_cn&edition=full","pubTime":"2026-05-19 09:36","pubTimestamp":1779154588,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物(06990)早盘涨超5%，截至发稿，涨4.71%，报444.2港元，成交额3844.07万港元。消息面上，默沙东宣布，其从科伦博泰引进的在研TROP2抗体偶联药物芦康沙妥珠单抗（sac‑TMT）用于特定晚期或复发性子宫内膜癌患者的III期TroFuse‑005研究已成功达到总生存期（OS）与无进展生存期（PFS）两项主要终点，并在关键次要终点客观缓解率（ORR）上同样取得积极结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | 科伦博泰生物(06990)早盘涨超5% 默沙东TROP2靶向ADC疗法3期临床成功","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0122379950.USD","IE00BJJMRZ35.SGD","BK1161","LU1571399168.USD","IE00BJT1NW94.SGD","LU1066051498.USD","LU1941712348.USD","LU0320765489.SGD","LU2361044865.SGD","LU1023059063.AUD","LU0965509101.SGD","LU2468319806.SGD","LU0477156953.USD","LU1116320737.USD","LU1934455863.HKD","LU0965509283.SGD","LU0965509010.AUD","BK4534","LU1093756325.SGD","LU1116320901.HKD","BK4516","LU1699723380.USD","LU0859254822.USD","LU0980610538.SGD","LU0868494708.USD","IE00B4R5TH58.HKD","LU0861579265.USD","LU0196878994.USD","SGXZ57979304.SGD","LU0289739699.SGD","BK4550","LU1934455277.USD","LU1162221912.USD","LU0070302665.USD","LU2089984988.USD","LU2357627491.SGD","LU2360032135.SGD","LU1066051811.HKD","LU1934455194.USD","SG9999014559.SGD","LU0985320562.USD","LU2125909593.SGD","SG9999001440.SGD","LU0203347892.USD","LU0238689110.USD","SG9999013999.USD","LU1941712264.USD","LU1291159041.SGD","LU0266013472.USD","LU2106854487.HKD","SG9999002224.SGD","LU1430594728.SGD","LU1917777945.USD","LU1989771016.USD","LU2461242641.AUD","IE00BLSP4452.SGD","LU2324357040.USD","SG9999001176.SGD","LU1057294990.SGD","LU0130102774.USD","IE00BFTCPJ56.SGD","LU0320765646.SGD","SG9999015358.SGD","LU1585245621.USD","LU2112291526.USD","LU1929549753.HKD","LU1061106388.HKD","LU1069347547.HKD","LU0058720904.USD","LU0203345920.USD","LU2125154935.USD","LU2491050071.SGD","IE00BN8TJ469.HKD","LU0098860793.USD","SG9999002232.USD","SG9999014575.USD","LU1983299246.USD","LU1066053197.SGD","LU2023250843.SGD","LU2361045086.USD","LU1037948541.HKD","LU2125909247.SGD","SG9999014542.SGD","IE000M9KFDE8.USD","IE00BLSP4239.USD","SG9999014567.USD","LU1037948897.HKD","BK4559","LU2023250504.SGD","LU1066051225.USD","LU0265550359.USD","LU1201861249.SGD","LU0211331839.USD","LU1989772840.SGD","BK4533","LU0648001328.SGD","SG9999001176.USD","IE00B2B36J28.USD","LU1923622614.USD","LU2491050154.USD","LU1093756168.USD","IE00B1BXHZ80.USD","LU0106261372.USD","BK4007","BK4585","LU2361044949.HKD","06990","LU2433249047.HKD","LU0006306889.USD","LU0130517989.USD","IE0002141913.USD","IE00BSNM7G36.USD","IE00BBT3K403.USD","LU0234572021.USD","LU1974910355.USD","SG9999015341.SGD","LU0942090050.USD","LU1989772923.USD","LU0432979614.USD","BK4231","LU1035773651.USD","LU0868494617.USD","BK4588","LU0965508806.USD","LU0265550946.USD","LU2125154778.USD","BK4080","LU2491049909.HKD","IE0009355771.USD","LU0208291251.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636074917","title":"科伦博泰生物(06990.HK)遭汇添富基金减持5.59万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2636074917","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636074917?lang=zh_cn&edition=full","pubTime":"2026-05-18 22:27","pubTimestamp":1779114422,"startTime":"0","endTime":"0","summary":"格隆汇5月18日丨根据联交所最新权益披露资料显示，2026年5月13日，科伦博泰生物(06990.HK)遭汇添富基金管理股份有限公司在场内以每股均价451.248港元减持5.59万股，涉资约2522.5万港元。\r\n\r\n　　减持后，汇添富基金管理股份有限公司最新持股数目为850.93万股，持股比例由5.01%下降至4.98%。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202605/18/20260518244316.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202605/18/20260518244316.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260518/32234042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU0196878994.USD","06990","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635793032","title":"新华健康｜科伦博泰生物：SKB118新药临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2635793032","media":"经济参考网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635793032?lang=zh_cn&edition=full","pubTime":"2026-05-14 14:33","pubTimestamp":1778740410,"startTime":"0","endTime":"0","summary":"5月13日，四川科伦博泰生物医药股份有限公司（证券简称“科伦博泰生物”，06990.HK）发布公告，公司已收到国家药品监督管理局（NMPA）药品审评中心（CDE）出具的临床试验通知书，同意公司就程序性细胞死亡蛋白-1（PD-1）×血管内皮生长因子（VEGF）双特异性抗体SKB118（又称CR-001）开展新药临床试验（IND），适应症为晚期实体瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605143737302477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0196878994.USD","06990","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://kelun-biotech.com","stockEarnings":[{"period":"1week","weight":-0.0257},{"period":"1month","weight":0.0048},{"period":"3month","weight":0.1926},{"period":"6month","weight":0.0123},{"period":"1year","weight":0.5049},{"period":"ytd","weight":0.178}],"compareEarnings":[{"period":"1week","weight":-0.0165},{"period":"1month","weight":-0.0356},{"period":"3month","weight":-0.0544},{"period":"6month","weight":-0.0262},{"period":"1year","weight":0.0683},{"period":"ytd","weight":-0.0175}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"四川科伦博泰生物医药股份有限公司是一家主要从事新药业务的研发、生产和销售的中国公司。该公司主要从事肿瘤学、免疫学及其他治疗领域的创新药物的研发、制造及商业化。该公司的产品有抗体药物偶联物（ADC）SKB264和A166等。该公司产品主要用于乳腺癌、非小细胞肺癌、胃肠道癌等疾病的治疗。","exchange":"SEHK","name":"科伦博泰生物","nameEN":"SKB BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科伦博泰生物(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科伦博泰生物(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科伦博泰生物,06990,科伦博泰生物股票,科伦博泰生物股票老虎,科伦博泰生物股票老虎国际,科伦博泰生物行情,科伦博泰生物股票行情,科伦博泰生物股价,科伦博泰生物股市,科伦博泰生物股票价格,科伦博泰生物股票交易,科伦博泰生物股票购买,科伦博泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科伦博泰生物(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科伦博泰生物(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}